An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Budigalimab in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Budigalimab (Primary) ; Telisotuzumab adizutecan (Primary) ; Carboplatin; Cisplatin; Pembrolizumab; Pemetrexed
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2025 New trial record